4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Recurrent bronchiectasis exacerbations are related to deterioration of lung function, progression of the disease, impairment of quality of life, and to an increased mortality. Improved detection of exacerbations has been accomplished in chronic obstructive pulmonary disease through the use of patient completed diaries. These tools may enhance exacerbation reporting and identification. The aim of this study was to develop a novel symptom diary for bronchiectasis symptom burden and detection of exacerbations, named the BEST diary.

          Methods

          Prospective observational study of patients with bronchiectasis conducted at Ninewells Hospital, Dundee. We included patients with confirmed bronchiectasis by computed tomography, who were symptomatic and had at least 1 documented exacerbation of bronchiectasis in the previous 12 months to participate. Symptoms were recorded daily in a diary incorporating cough, sputum volume, sputum colour, dyspnoea, fatigue and systemic disturbance scored from 0 to 26.

          Results

          Twenty-one patients were included in the study. We identified 29 reported (treated exacerbations) and 23 unreported (untreated) exacerbations over 6-month follow-up. The BEST diary score showed a good correlation with the established and validated questionnaires and measures of health status (COPD Assessment Test, r = 0.61, p = 0.0037, Leicester Cough Questionnaire, r = − 0.52, p = 0.0015, St Georges Respiratory Questionnaire, r = 0.61, p < 0.0001 and 6 min walk test, r = − 0.46, p = 0.037). The mean BEST score at baseline was 7.1 points (SD 2.2). The peak symptom score during exacerbation was a mean of 16.4 (3.1), and the change from baseline to exacerbation was a mean of 9.1 points (SD 2.5). Mean duration of exacerbations based on time for a return to baseline symptoms was 15.3 days (SD 5.7). A minimum clinically important difference of 4 points is proposed.

          Conclusions

          The BEST symptom diary has shown concurrent validity with current health questionnaires and is responsive at onset and recovery from exacerbation. The BEST diary may be useful to detect and characterise exacerbations in bronchiectasis clinical trials.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: found

          The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions

          Bronchiectasis is a clinical and radiological diagnosis associated with cough, sputum production and recurrent respiratory infections. The clinical presentation inevitably overlaps with other respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). In addition, 4–72% of patients with severe COPD are found to have radiological bronchiectasis on computed tomography, with similar frequencies (20–30%) now being reported in cohorts with severe or uncontrolled asthma. Co-diagnosis of bronchiectasis with another airway disease is associated with increased lung inflammation, frequent exacerbations, worse lung function and higher mortality. In addition, many patients with all three disorders have chronic rhinosinusitis and upper airway disease, resulting in a complex “mixed airway” phenotype. The management of asthma, bronchiectasis, COPD and upper airway diseases has traditionally been outlined in separate guidelines for each individual disorder. Recognition that the majority of patients have one or more overlapping pathologies requires that we re-evaluate how we treat airway disease. The concept of treatable traits promotes a holistic, pathophysiology-based approach to treatment rather than a syndromic approach and may be more appropriate for patients with overlapping features. Here, we review the current clinical definition, diagnosis, management and future directions for the overlap between bronchiectasis and other airway diseases.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations

              Asthma exacerbations are frightening for patients and are occasionally fatal. We tested the concept that a plan for patients to manage their asthma (self-management plan), which included a temporary quadrupling of the dose of inhaled glucocorticoids when asthma control started to deteriorate, would reduce the incidence of severe asthma exacerbations among adults and adolescents with asthma.
                Bookmark

                Author and article information

                Contributors
                jchalmers@dundee.ac.uk
                Journal
                Respir Res
                Respir. Res
                Respiratory Research
                BioMed Central (London )
                1465-9921
                1465-993X
                13 January 2020
                13 January 2020
                2020
                : 21
                : 18
                Affiliations
                [1 ]Department of Respiratory Medicine, Galdakao-Usansolo Hospital, Galdakao, Bizkaia Spain
                [2 ]ISNI 0000 0004 0397 2876, GRID grid.8241.f, Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, Division of Molecular and Clinical Medicine, , University of Dundee, ; DD1 9SY Dundee, Scotland
                [3 ]AZ Nikolaas, Sint-Niklaas, Belgium
                [4 ]ISNI 0000 0004 1757 2822, GRID grid.4708.b, Department of Pathophysiology and Transplantation, , University of Milan, ; Milan, Italy
                [5 ]ISNI 0000 0004 1757 8749, GRID grid.414818.0, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, ; Milan, Italy
                Article
                1272
                10.1186/s12931-019-1272-y
                6958700
                31931782
                ad55a055-2b9c-470c-863c-3ebd4db1c3ed
                © The Author(s). 2020

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 23 October 2019
                : 29 December 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100008593, European Respiratory Society;
                Award ID: CRC-2013
                Categories
                Research
                Custom metadata
                © The Author(s) 2020

                Respiratory medicine
                bronchiectasis,exacerbations,unreported exacerbations,symptom diary
                Respiratory medicine
                bronchiectasis, exacerbations, unreported exacerbations, symptom diary

                Comments

                Comment on this article